Expansion of Nucleic Acid Products Across EMEA
TriLink BioTechnologies, a Maravai LifeSciences company specializing in life science reagents and services, has announced a strategic partnership with Avantor, a global provider of essential products and services for the life sciences and advanced technology industries. This collaboration aims to enhance the availability of TriLink’s innovative nucleic acid technologies across Europe, the Middle East, and Africa (EMEA). By leveraging Avantor’s extensive distribution network, the partnership is expected to streamline the ordering process and reduce lead times for customers in these regions, thereby accelerating research and development in the field of nucleic acids.
With a legacy of over 25 years in nucleic acid development, TriLink has built a strong reputation for pioneering advancements in mRNA-based therapeutics. The agreement will now make a range of TriLink’s high-quality products—including CleanCap® cap analogs for mRNA capping, catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes such as CleanScribe® RNA Polymerase—more widely accessible. These products can be used for research purposes or manufactured at GMP-grade standards. In addition, TriLink’s offerings will soon be available on Avantor’s eCommerce platform, MarketSource, making procurement even more convenient for researchers and institutions.
Industry Leaders Collaborate for Innovation
Commenting on the partnership, Becky Buzzeo, Chief Commercial Officer at TriLink, emphasized the importance of expanding access to cutting-edge nucleic acid solutions. She highlighted that by collaborating with Avantor, TriLink can more effectively meet the growing demand for advanced research materials, ultimately supporting breakthroughs in therapeutic development. Avantor, known for its robust global reach, will play a crucial role in ensuring the timely delivery and accessibility of TriLink’s products to customers in EMEA.
TriLink remains committed to advancing nucleic acid therapeutics, vaccines, and diagnostics. The company’s expertise spans mRNA capping analogs, nucleotides, IVT enzymes, and scale-up capabilities, catering to the evolving needs of the biotechnology and pharmaceutical industries. The expansion of TriLink’s distribution network is expected to empower researchers by providing them with high-quality tools necessary for developing innovative treatments in various medical fields.
Driving the Future of Nucleic Acid Research
TriLink BioTechnologies, as part of Maravai LifeSciences, is recognized as a global leader in nucleic acid and mRNA solutions. The company provides chemical and biological expertise along with Contract Development and Manufacturing Organization (CDMO) services. Its patented CleanCap® mRNA capping technology is widely used in developing vaccines and therapeutics for infectious diseases, oncology, cardiology, and neurological disorders.
Avantor, a prominent player in the life sciences sector, supports critical research and production activities across 180 countries. The company’s extensive portfolio serves more than 300,000 customer locations, making it a key partner for scientific advancements. Through this collaboration, both organizations aim to accelerate the pace of innovation in nucleic acid research and contribute to groundbreaking medical advancements in the years ahead.
Read Also: New Proteomic Age Clock Reveals Insights into Biological Aging and Health Risks
